attractive potential addition to combination therapeutic regimens, including radiation therapy, oncolytic viral therapy, immune checkpoint inhibition, and autologous tumor vaccines, and warrants further clinical…
Background: Immune-checkpoint-inhibitors (ICPIs) represent a novel class of immunotherapy against several malignancies that changed the treatment of cancer and improved the patient’s outcome. However these agents
host. This concept, has led investigators to design several clinical trials using immune checkpoint inhibitors (ICI) in early (ECB) and metastatic (MBC) BrCa. Unlike in other cancers, there
case of MSI high and one (1) TRK fusion positive tumor, eligible for checkpoint inhibitor and TRK inhibitor therapy respectively. Moreover, tumor NGS identified 16 (15%) cases of MEN1
Immunotherapy, represented by immune checkpoint inhibitors (ICI), is transforming the treatment of cancer. However, only a small percentage of patients show response to ICI and there is an unmet need
plausible. We recently demonstrated that these regulatory NK cells express CD73 a metabolic immune checkpoint together with proteins involved in tumor immune suppression. While the characteristics of regulatory NK cells
contribution of this massive amount of information to alter the standard of care. Immune checkpoints have gained attention in the recent years in the oncology field as a presumable mechanism
specific, it is hazy how auto reactive B cells emerge and elude resilience checkpoints that ordinarily control their improvement and extension. Whereas temporal, short-lived autoreactive B-cell reactions
Immunotherapy is now accepted as a new treatment modality for cancer. US FDA approved checkpoint blockage, anti- CTLA4 and anti-PD1/L1, monoclonal antibody drugs and autologous CAR-T cells
advanced in ovarian malignant growth treatment by consolidating with different treatments, for example, safe checkpoint inhibitors [9-11], chemotherapy [12,13] and assenting T cell treatment
field of hepatocellular carcinoma (HCC) immunotherapy has made progress whereas negative checkpoint regulators restrict T-cell responses. Programmed death-1 homolog (PD–1H) has been shown to suppress T–cell
PP2A) is a crucial regulator of the cellular signalling pathways, proliferation, cell cycle checkpoints and apoptosis. The PPP2R5C gene encodes PP2A regulatory B56c subunit. Malignant transformation may occur, if mRNA
PP2A) is a crucial regulator of the cellular signalling pathways, proliferation, cell cycle checkpoints and apoptosis. The PPP2R5C gene encodes PP2A regulatory B56c subunit. Malignant transformation may occur, if mRNA
binding cassette (ABC) is one of the greatest families of transporters involved in these “checkpoints.” They are located in all residing species and use ATP hydrolysis to transport a wide
combinatory immunotherapies is a promising area of research, and includes the combination of immune checkpoint inhibitors with cytotoxic therapies, cancer vaccines and monoclonal antibodies against other co- inhibitory
Cancer cells can induce a state of immunotolerance, which may be reversed by checkpoint blocker immunotherapy. Prediction of immunotherapy response remains a challenge. CD4+ lymphocytes are important for activating
found its involvement in prevention but not reversal of AID. Another group of immune checkpoint protein, the PD-1/PD-L1 axis, has been found to down-regulate immune response
frequency of immune checkpoint inhibitor (ICI) use in lung cancer chemotherapy has increased and has been associated with an increasing frequency of Immune-Related Adverse Events (IRAEs). Although IRAEs mainly
success of checkpoint inhibitors in cancer therapy is largely attributed to activating the patient’s immune response to their tumor’s neoantigens arising from DNA mutations. This realization has motivated
currently ongoing about the compatibility between oncolytic virotherapy, chemotherapy like paclitaxel for breast cancer checkpoint inhibitors in patients with melanoma. In general, oncolytic virus treatment has a safety…
clinical trials led to date to disappointing results. The immunotherapeutic intervention targeting T-cell checkpoint molecules has been proposed as well, but results obtained indicate that ACC patients would
For authors and organisers
Publish, present and keep up with your field
Find the right journal for your paper and submit your manuscript.